Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 10,331,073 shares, an increase of 144.0% from the July 30th total of 4,234,144 shares. Approximately 1,266.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 60,973,817 shares, the days-to-cover ratio is currently 0.2 days.

Liminatus Pharma Stock Performance

Shares of NASDAQ:LIMN opened at $4.49 on Friday. The stock has a market capitalization of $4.53 million, a price-to-earnings ratio of -0.19 and a beta of 5.35. Liminatus Pharma has a 1-year low of $4.26 and a 1-year high of $154.50. The company has a 50 day moving average price of $5.73 and a 200 day moving average price of $9.56.

Liminatus Pharma (NASDAQ:LIMN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.50) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

A number of research firms recently issued reports on LIMN. Wall Street Zen lowered Liminatus Pharma to a “strong sell” rating in a report on Saturday, August 22nd. Weiss Ratings raised shares of Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.